<DOC>
	<DOCNO>NCT00748969</DOCNO>
	<brief_summary>The purpose study determine whether growth hormone safe effective treatment short stature child Mucopolysaccharidosis type I , II , VI .</brief_summary>
	<brief_title>Clinical Trial Growth Hormone MPS I , II , VI</brief_title>
	<detailed_description>Although child MPS I , II , VI treat Hematopoietic Cell Transplantation ( HCT ) and/or enzyme replacement therapy ( ERT ) living adulthood good cognitive development , quality life significantly impact skeletal abnormality ( i.e. , kyphosis , scoliosis , genu valgum ) , contracture , severe short stature . Here University Minnesota see promise clinical outcome child MPS IH treat human growth hormone ( hGH ) . There currently report literature impact treat child MPS short stature , hGH growth velocity characteristic skeletal abnormality . This study advance care child provide data yet unexplored area pediatric medicine goal improve quality life child improve height , mobility , neuropsychological functioning . This Phase II/III randomize , single-center , 12 month clinical trial growth hormone male female participant MPS I , II , VI , follow 12 month open label . Participants height ≤ -2 SDS age gender randomize first 12 month 1:1 treatment treatment . At conclusion 12 month , subject offer additional 12 month treatment .</detailed_description>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>A parent legally authorize representative must provide write informed consent comply study assessment full duration study . Chronologic age ≥ 5 year bone age ≤12 year Diagnosis MPS I , II , VI Height ≤ 2 SDS age gender Ability travel study center evaluation . Ability participant cooperate study procedure , notify guardian symptom , provide assent participation study . History treatment hGH Untreated pituitary deficiency Pregnancy ( positive urine pregnancy test ) prior enrollment study Participation another simultaneous medical intervention trial Patients close epiphysis Active neoplasm Orthopedic procedure femur within last 6 month . Known suspect allergy trial product relate product . Structural lesion brain MRI result brain compression Any social medical condition investigator believe would pose significant hazard subject investigational therapy initiate detrimental study . Obstructive sleep apnea without BiPAP tonsillectomy/adenoidectomy treatment . CNS shunt . Abnormal cardiac function base echocardiogram within 6 month prior enrollment : Ejection fraction le 50 % Left ventricular chamber size great less 2 standard deviation normal body surface area Left ventricular wall thickness great less 2 standard deviation normal body surface area More mild moderate aortic insufficiency abdominal aortic runoff More mild moderate mitral insufficiency pulmonary hypertension Abnormal pulmonary function base pulmonary function test within 6 month prior enrollment : abnormal FVC &lt; 80 % predicted age , gender , height abnormal FEV1 &lt; 80 % predicted age , gender , height abnormal FEV1/FVC abnormal oxygen saturation</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>MPS I</keyword>
	<keyword>MPS II</keyword>
	<keyword>MPS VI</keyword>
	<keyword>growth hormone</keyword>
	<keyword>short stature</keyword>
</DOC>